Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


13.05.2019

1 Ann Oncol
1 Ann Surg Oncol
2 BMC Cancer
1 Cancer Sci
1 Carcinogenesis
1 Chest
2 Clin Cancer Res
1 Clin Lung Cancer
1 Int J Cancer
1 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
4 J Thorac Oncol
1 Lancet
1 Lung Cancer
1 Mol Carcinog
4 Oncogene
3 Oncol Rep
1 Oncologist
1 PLoS One
1 Proc Natl Acad Sci U S A
2 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
    A Phase 3, Randomized, Open-label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer.
    Ann Oncol. 2019 May 9. pii: 5487410. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. XIE HJ, Zhang X, Mo YX, Long H, et al
    Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2019 May 3. pii: 10.1245/s10434-019-07412.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. BORCHERT S, Wessolly M, Schmeller J, Mairinger E, et al
    Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    BMC Cancer. 2019;19:108.
    PubMed     Text format     Abstract available

  4. SUWINSKI R, Giglok M, Galwas-Kliber K, Idasiak A, et al
    Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
    BMC Cancer. 2019;19:427.
    PubMed     Text format     Abstract available


    Cancer Sci

  5. YU S, Yang D, Ye Y, Liu P, et al
    lncRNA AFAP1-AS1 promotes malignant phenotype through binding with LSD1 and repressing HBP1 in non-small cell lung cancer.
    Cancer Sci. 2019 May 8. doi: 10.1111/cas.14039.
    PubMed     Text format     Abstract available


    Carcinogenesis

  6. BARTA JA, Pauley K, Kossenkov AV, McMahon SB, et al
    The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Carcinogenesis. 2019 May 8. pii: 5487200. doi: 10.1093.
    PubMed     Text format     Abstract available


    Chest

  7. WIENER RS, Rivera MP
    Access to Lung Cancer Screening Programs in the United States: Perpetuating the Inverse Care Law.
    Chest. 2019;155:883-885.
    PubMed     Text format    


    Clin Cancer Res

  8. SALEM A, Little RA, Latif A, Featherstone AK, et al
    Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer.
    Clin Cancer Res. 2019 May 3. pii: 1078-0432.CCR-18-3932.
    PubMed     Text format     Abstract available

  9. DATAR IJ, Sanmamed MF, Wang J, Henick BS, et al
    Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
    Clin Cancer Res. 2019 May 3. pii: 1078-0432.CCR-18-4142.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  10. DUDNIK E, Bar J, Peled N, Bshara E, et al
    Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Clin Lung Cancer. 2019 Apr 5. pii: S1525-7304(19)30080.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. DIETZ S, Lifshitz A, Kazdal D, Harms A, et al
    Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.
    Int J Cancer. 2019;144:1061-1072.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  12. CHO JH, Jung HA, Lee SH, Ahn JS, et al
    Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
    J Cancer Res Clin Oncol. 2019;145:1341-1349.
    PubMed     Text format     Abstract available


    J Clin Oncol

  13. GOMEZ DR, Tang C, Zhang J, Blumenschein GR Jr, et al
    Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
    J Clin Oncol. 2019 May 8:JCO1900201. doi: 10.1200/JCO.19.00201.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  14. MOORE CB, Cox ML, Mulvihill MS, Klapper J, et al
    Challenging 30-day mortality as a site-specific quality metric in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 Mar 28. pii: S0022-5223(19)30702.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  15. VARGHESE C, Rajagopalan S, Karwoski RA, Bartholmai BJ, et al
    Computed Tomography based Score Indicative of Lung Cancer Aggression (SILA) Predicts the Degree of Histological Tissue Invasion and Patient Survival in Lung Adenocarcinoma Spectrum.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30355.
    PubMed     Text format     Abstract available

  16. THOMAS A, Vilimas R, Trindade C, Erwin-Cohen R, et al
    Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361.
    PubMed     Text format     Abstract available

  17. KATSUMATA S, Aokage K, Ishii G, Nakasone S, et al
    Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of non-small cell lung cancer.
    J Thorac Oncol. 2019 May 2. pii: S1556-0864(19)30313.
    PubMed     Text format     Abstract available

  18. CANNON-ALBRIGHT LA, Carr SR, Akerley W
    Population-based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer.
    J Thorac Oncol. 2019 May 7. pii: S1556-0864(19)30316.
    PubMed     Text format     Abstract available


    Lancet

  19. SMIT EF, de Langen AJ
    Pembrolizumab for all PD-L1-positive NSCLC.
    Lancet. 2019;393:1776-1778.
    PubMed     Text format    


    Lung Cancer

  20. LAN S, Li H, Liu Y, Ma L, et al
    Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.
    Lung Cancer. 2019 Apr 28. pii: S0169-5002(19)30426.
    PubMed     Text format    


    Mol Carcinog

  21. XU L, Qiu S, Yang L, Xu H, et al
    Aminocyanopyridines as anti-lung cancer agents by inhibiting the STAT3 pathway.
    Mol Carcinog. 2019 May 8. doi: 10.1002/mc.23038.
    PubMed     Text format     Abstract available


    Oncogene

  22. MATSUSHITA A, Sato T, Mukai S, Fujishita T, et al
    TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Oncogene. 2019;38:1966-1978.
    PubMed     Text format     Abstract available

  23. ZHANG C, Wang H, Liu X, Hu Y, et al
    Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP.
    Oncogene. 2019;38:1892-1904.
    PubMed     Text format     Abstract available

  24. LEE E, Ouzounova M, Piranlioglu R, Ma MT, et al
    The pleiotropic effects of TNFalpha in breast cancer subtypes is regulated by TNFAIP3/A20.
    Oncogene. 2018 Aug 30. pii: 10.1038/s41388-018-0472.
    PubMed     Text format     Abstract available

  25. WENG CH, Chen LY, Lin YC, Shih JY, et al
    Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Oncogene. 2019;38:455-468.
    PubMed     Text format     Abstract available


    Oncol Rep

  26. OTA K, Okuma T, Lorenzo A, Yokota A, et al
    Fingolimod sensitizes EGFR wildtype nonsmall cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
    Oncol Rep. 2019 May 2. doi: 10.3892/or.2019.7140.
    PubMed     Text format     Abstract available

  27. GRZEGRZOLKA J, Gomulkiewicz A, Olbromski M, Glatzel-Plucinska N, et al
    Expression of tesmin (MTL5) in nonsmall cell lung cancer: A preliminary study.
    Oncol Rep. 2019 May 2. doi: 10.3892/or.2019.7145.
    PubMed     Text format     Abstract available

  28. LU G, Cao L, Zhu C, Xie H, et al
    Improving lung cancer treatment: Hyaluronic acidmodified and glutathioneresponsive amphiphilic TPGSdoxorubicin prodrugentrapped nanoparticles.
    Oncol Rep. 2019 May 2. doi: 10.3892/or.2019.7139.
    PubMed     Text format     Abstract available


    Oncologist

  29. FURUTA M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, et al
    Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Oncologist. 2019 May 8. pii: theoncologist.2018-0676.
    PubMed     Text format     Abstract available


    PLoS One

  30. HUANG MH, Blackwood J, Godoshian M, Pfalzer L, et al
    Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
    PLoS One. 2018;13:e0208573.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  31. MONSIVAIS D, Peng J, Kang Y, Matzuk MM, et al
    Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
    Proc Natl Acad Sci U S A. 2019;116:3883-3892.
    PubMed     Text format     Abstract available


    Thorax

  32. ZHANG J, Dong A, Cui Y, Wang Y, et al
    Diffuse cavitary benign metastasising leiomyoma of the lung.
    Thorax. 2019;74:208-209.
    PubMed     Text format    

  33. ONG P, Grosu HB, Debiane L, Casal RF, et al
    Long-term quality-adjusted survival following therapeutic bronchoscopy for malignant central airway obstruction.
    Thorax. 2019;74:141-156.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: